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Summary
The transition period from the hospital to the outpatient
setting is a critical phase when managing heart failure. A
well-structured transition is paramount and helps to en-
sure a tight follow-up schedule for the heart failure patient,
thereby improving treatment outcomes. This article aims
to provide guidance for the first three follow-up visits after
hospital discharge, with a focus on monitoring heart failure
patients and up-titrating their medication in primary care.
Keywords: heart failure, patients, hospital discharge
Introduction
Heart failure (HF) is a serious chronic condition associated
with periodic exacerbations leading to frequent hospitali-
sation [1]. Indeed, it is the leading cause of hospitalisation
in patients over 65 years of age [1–3]. HF patients are dis-
charged from the hospital in a vulnerable phase charac-
terised by high mortality and morbidity. In a Swiss trial,
approximately 20% of HF patients were readmitted to the
hospital within the first 30 days of discharge [4]. Similarly,
data gathered from two other studies conducted in Switzer-
land showed that at 3 months mortality was 18% and the
rate of rehospitalisation was 26% [3, 5].
Several strategies have been developed to reduce mortality
and morbidity during the vulnerable post-discharge period,
including coordinated discharge planning and the devel-
opment of a well-structured follow-up treatment plan [1].
This seems to be an area where cardiology could learn a
lot from oncology with its predefined treatment schedules
aiming to best balance treatment efficacy and tolerabili-
ty. An integrative and collaborative patient care approach
following hospital discharge has been shown to reduce
the mortality risk by approximately 50% (from 15.5% to
7.2%) [6]. In particular, prescheduled follow-up visits, ad-
herence to therapy and up-titration of HF medication are
important aspects of reducing the mortality risk during the
transition phase after hospital discharge [1]. Consequent-
ly, according to European Society of Cardiology (ESC)
Guidelines, patients with chronic HF should be followed
up in a multidisciplinary environment (evidence level IA)
in which general practitioners (GPs) and cardiologists play
a key role [1, 7, 8].
The aim of this consensus paper is to set clear treatment
targets for the first three follow-up visits, and to provide
GPs and cardiologists with recommendations for an opti-
mal patient follow-up during the transition phase after dis-
charge of HF patients hospitalised for acute decompensa-
tion in Switzerland. We address the aspect of feasibility,
highlighting current hurdles for implementation, and also
concepts on how to overcome them. In particular, these
recommendations also provide guidance on the optimal
monitoring of HF patients when up-titrating HF medica-
tion, which may be challenging owing to its tolerability,
concomitant comorbidities and polypharmacy. The recom-
mendations for monitoring apply universally to all HF pa-
tients, whereas the recommendations for up-titration of
disease-modifying drugs are specific for HF with reduced
ejection fraction (HFrEF)
The benefit of a well-structured transition
phase
There is a growing body of evidence suggesting that HF
patients are particularly vulnerable to disruptions in care
Correspondence:
Prof. Christian Müller, MD,
Universitätsspital Basel,
Klinik für Kardiologie, Pe-
tersgraben 4, CH-4031
Basel,
Chmueller[at]uhbs.ch
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 1 of 9
during the transition phase [7, 9, 10]. For example, it has
been shown that readmission rates can be reduced if the
first outpatient follow-up visit is scheduled prior to hos-
pital discharge [1]. In line with this study, the 2016 ESC
guidelines for acute and chronic HF propose a care plan en-
suring a well-structured transition phase to improve treat-
ment outcomes [1].
The criteria for a well-structured transition phase are de-
tailed in figure 1. The discharge letter ideally provides in-
formation on the clinical course including body weight,
blood pressure, potassium and renal function prior to dis-
charge, the therapy initiated in hospital and – importantly
– recommendations on the follow-up schedule and up-
titration strategy [1, 11]. The HF diary developed by the
Schweizerische Herzstiftung should be given to the patient
at discharge or at the latest at the first outpatient visit, as
it contributes to a well-structured transition from hospital
to primary care [12]. In the HF patient’s daily diary, “My
heart diary”, provided by the Swiss Heart Failure founda-
tion, the patient can (or should) record body weight, blood
pressure, heart rate, and other symptom-related observa-
tions [13]. It is suggested that patients bring their HF di-
ary to each follow-up visit with their GP or cardiologist.
Another cornerstone of the HF diary is a detailed medica-
tion plan. This plan should list the prescribed drugs, in-
cluding their active substances and brand names, as well
as provide instructions on how and when the drugs should
be taken. The GP and the cardiologist should be notified
whether the patient has been informed about the prognosis
of the disease while still at hospital or if the patient has
expressed wishes regarding life-prolonging measures and
palliative care [14]. In the case of patients with severe HF,
the patient, the cardiologist and the GP should be involved
in the decision to transition to palliative care. However, it
is challenging to select the time-point for this transition as
symptoms and quality of life keep changing for HF pa-
tients. Thus, it is recommended to regularly assess the pa-
tients and analyse their palliative scores, which provide an
objective assessment of the patient’s condition [1].
To ensure a timely follow-up schedule, a collaborative care
network with HF specialists, cardiologists and GPs should
be established. Consistently with the 2016 ESC guidelines
on HF, the present author group recommends that the first
follow-up visit take place within the first 7–10 days after
hospital discharge [1]. Patients with severe HF, however,
should see a GP or cardiologist within 1–3 days [15–17].
Recommendations for monitoring HF patients beyond the
first follow-up visit are currently limited and depend on the
individual patient’s needs. This author group further sug-
gests that the second visit take place 7–10 days after the
first visit. The interval between follow-up visits can be in-
creased for the third and later follow-up visits depending
on the patient’s clinical status. A referral to a cardiologist,
on the other hand, is recommended every 3 months for
patients with New York Heart Association (NYHA) stage
III–IV HF [18, 19].
Together these measures ensure a close collaboration be-
tween GPs and cardiologists, thus enabling HF patients to
receive the right support and care after hospital discharge.
Furthermore, these measures are a prerequisite for optimal
follow-up and up-titration strategies and, therefore, con-
tribute to reducing the risk of death or rehospitalisation [1].
Feasibility
Several hurdles for implementation exist. First, most GPs/
cardiologists have busy schedules, making it challenging
to add on additional patients at rather short notice. Second,
GPs/cardiologists may not have all relevant medical infor-
Figure 1: Up-titration roadmap for patients with HFrEF. ACEI = angiotensin-converting-enzyme inhibitor; AE = adverse event; AHA =
American Heart Association; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; BB = beta blockers; ESC =
European Society of Cardiology; GP = General Practitioner; HFrEF = heart failure (HF) with reduced ejection fraction; MRA = mineralocorti-
coid receptor antagonist; PCP = primary care physician. Based on the scientific content of the publications from Hickey 2016 [45] with data
from Ponikowski et al. 2016 [1], Yancy 2013/2017 [47, 48] and the Canadian Cardiovascular Society 2017 [30].
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mation of the recent hospitalisation available early on af-
ter discharge owing to delays in the finalisation of the dis-
charge letter or lack of details in the discharge letter (e.g.,
missing details on body weight, blood pressure, potassi-
um and renal function). Third, some patients may not have
a GP/cardiologist at the time of hospitalisation. Fourth,
frailty may limit the ability of the patient to visit the office
of the GP/cardiologist.
For successful implementation of the transition pro-
gramme, each of these hurdles must be addressed and ulti-
mately overcome. To improve practical feasibility, the im-
plementation of cardiology and/or HF networks that share
patient information and use common electronic health
records, joint online booking systems for GP/cardiology
slots (similar to those used extensively to book hotel rooms
worldwide), such as docbox, nurse-coordinated HF man-
agement programmes [20, 21], and tele-monitoring pro-
grammes, such as the Swiss Care4Cardio, will all have im-
portant roles [22, 23].
General assessments during follow-up visits
Recommended assessments to be performed during the
first three follow-up visits with the GP or the cardiologist
are summarised in table 1 [1]. These include the evaluation
of risk factors that increase the risk of rehospitalisation due
to HF. Monitoring of physical symptoms (rales, oedema,
body weight changes), laboratory parameters (B-type na-
triuretic peptide [BNP] or N-terminal pro b-type natriuret-
ic peptide [NT-pro-BNP], electrolytes, haemoglobin, renal
function), and drug-related adverse events (hypotension,
hyperkalaemia, worsening renal function) are likewise of
particular relevance [1, 26].
Patient education
The follow-up visits should also be used to educate the HF
patients on the importance of self-monitoring body weight
and other signs /symptoms of deterioration. Besides the
“heart failure diary”, patients may use apps, such “life with
heart failure” or the “electronic heart failure diary”, for
self-monitoring [27]. This authors group considers patient
education and empowerment an import pillar of HF man-
agement. In addition, patients need to learn how to react to
imminent decompensation (calling their GP, self-adjusting
the diuretic dose).
Medication management after hospital dis-
charge
The importance of up-titration after hospital discharge
Treatment of HF with angiotensin converting-enzyme in-
hibitors (ACEIs), or angiotensin II receptor blockers
(ARBs) if the ACEI is not tolerated, angiotensin receptor-
neprilysin inhibitor (ARNI), beta-blockers and mineralo-
corticoid receptor antagonists (MRAs) form the basis of
the management of patients with HFrEF (fig. 2). Adjust-
ment and up-titration of these therapeutic agents are criti-
cal for successful HF management. Based on pivotal trials,
the 2016 ESC guidelines on HF recommend tight follow-
up and up-titration schedules until the highest tolerated
dose is achieved [1]. However, only a minority of patients
enrolled in the ESC Heart Failure Long-Term Registry re-
ceived the target dose of an ACEI (29% of patients) or be-
ta-blocker (18% of patients) despite their positive impact
[28]. Conversely, a careful reduction of loop diuretics may
be feasible in the majority of stable chronic HF patients
without signs of volume overload [29].
Table 1: Assessments in primary care for monitoring HF patient status.
Assessments to monitor
patient status [16, 24]
Patient well-being Physical and social activities, independent care (e.g., ability to climb stairs, carry groceries, jog or run [as
if to catch a bus], do housework or gardening, walk a certain distance on level ground, have sex, dress,
shower/bathe)
Symptoms such as shortness of breath, swelling in your feet, ankles, legs, fatigue
Patient education / self-care The patient should be aware of the importance of self-monitoring and documenting their body weight on a
daily basis.
Life-style: physical activity
Knowledge about “red flags” and what to do if any of the following warning signs occur:
‒ increase in body weight
‒ dyspnoea
‒ fainting
‒ worsening symptoms
Palliative care: Patients with late-stage HF should be informed about palliative care options
Therapy adherence Verify medication plan and adherence to prescribed therapy
Verify whether the patient would benefit from additional measures, such as a dosette boxe or home-care
support
Assessments to monitor
HF status [16, 19, 25]
Cardiac function Heart rate and heart rhythm
Laboratory assessments Kidney function (eGFR and SCr)
Serum electrolytes (potassium)
Clinical assessments Body weight
Jugular venous pressure, crackling in the lungs (these provide valuable insights for adjusting diuretic ther-
apy)
Peripheral oedema
Blood pressure (to assess potential orthostatic hypotension)
Palpitations
Volume status
eGFR = estimated glomerular filtration rate; HF = heart failure; SCr = serum creatinine; NYHA: New York Heart Association
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Guidance on up-titrating heart failure medication
Table 2 provides both GPs and cardiologists with a check-
list for initiating and up-titrating HF medication. An
overview is depicted in figure 1. This up-titration strategy
should be followed in all HFrEF patients as long as the
therapy is tolerated. The up-titration strategy should be ad-
justed in the case of adverse events such as hypotension,
hyperkalaemia or worsening renal function [1, 30]. Rec-
ommendations for adjusting HF medication in HFrEF pa-
tients experiencing such adverse events are summarised in
table 3.
Management of adverse events is part of the up-titration
strategy. Patients with asymptomatic hypotension (systolic
blood pressure [SBP] 90–100 mm Hg) usually do not re-
quire any changes to therapy [45]. In patients with sympto-
matic hypotension (characterised by dizziness, light-head-
Figure 2: Treatment algorithms of symptomatic HFrEF patients [1].ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II
receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; CRT = cardiac resynchronisation therapy; HFrEF = heart failure with re-
duced ejection fraction; H-ISDN = hydralazine and isosorbide dinitrate; HR = heart rate; ICD = implantable cardioverter defibrillator; LVAD =
left ventricular assist device; LVEF = left ventricular ejection fraction; MR = mineralocorticoid receptor; OMT = optimal medical therapy; VF =
ventricular fibrillation; VT = ventricular tachycardia.a Symptomatic = NYHA Class II-IV. b HFrEF = LVEF <40%. c If ACEI not tolerated / con-
traindicated, use ARB. d If MR antagonist not tolerated / contraindicated, use ARB. e With a hospital admission for HF within the last 6 months
or with elevated natriuretic peptides (BNP >250 pg/ml or NTproBNP >500 pg/ml in men and 750 pg/ml in women). f With an elevated plasma
natriuretic peptide level (BNP ≥150 pg/ml or plasma NT-proBNP ≥600 pg/ml, or if HF hospitalisation within recent 12 months plasma BNP
≥100 pg/ml or plasma NT-proBNP ≥400 pg/ml). g In doses equivalent to enalapril 10 mg b.i.d. h With a hospital admission for HF within the pre-
vious year. I CRT is recommended if QRS ≥130 msec and LBBB (in sinus rhythm). j CRT should/may be considered if QRS ≥130 msec with
non-LBBB (in a sinus rhythm) or for patients in AF provided a strategy to ensure bi-ventricular capture in place (individualised decision).
Adapted from Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and
chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129–200 [1].
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edness and confusion; SBP ≤90 mm Hg), however,
treatment with nitrates, calcium-channel blockers and oth-
er vasodilators should be either stopped entirely or admin-
istered at reduced doses [45].
The probability for symptomatic hypotension is increased
in patients with volume and sodium depletion [31–33,
35–37, 44]. Therefore, a reduction of the diuretic dose
should be considered in compensated patients not showing
signs or symptoms of congestion [45]. If these measures do
not improve the patient’s clinical status, the dose of ACEi,
ARB, ARNI or beta-blocker may be temporarily reduced
in a step-by-step manner [38–41] and the patient has to
be reassessed within one week [45]. Renal insufficiency
may also increase the risk of hypotension [32, 35]. Fur-
thermore, postural hypotension in HF patients with auto-
nomic dysfunction or stroke can limit the optimal dosing
of HF medication [1]. In these patients, a reduction of the
diuretic dose may reduce the severity of the interaction [1].
Treatment of other pharmacological conditions such as de-
pression (tricyclic antidepressants) or prostatic obstruction
(alpha-adrenoceptor blockers) may cause hypotensive in-
teractions with HF medication [1].
As hyperkalaemia may occur in HF patients, regular mon-
itoring of serum potassium levels is necessary [1]. Partic-
ularly in dehydrated or septic patients, serum potassium,
creatinine and urea levels should be closely followed [45].
Additional risk factors for hyperkalaemia include age, re-
nal failure and diabetes mellitus [43]. If serum potassium
levels increase to ≥5.5 mmol/l, the doses of potassium-
retaining agents and renin-angiotensin-aldosterone system
(RAAS) inhibitors should be halved and levels rechecked
after few days. Short term cessation is required if potas-
sium rises to >6.0 mmol [1]. However, RAAS inhibitors
should be reintroduced as soon as possible with continued
close monitoring of potassium levels [1].
Furthermore, worsening renal function or chronic kidney
disease (CKD) are also commonly seen among HF patients
[1]. Both CKD and HF share many risk factors, including
diabetes, hypertension and hyperlipidaemia [1]. Heart fail-
ure patients are more vulnerable to acute renal failure fol-
lowing a destabilising event, such as a dehydrating illness,
over-diuresis or the addition of nephrotoxic medication
(e.g., antibiotics such as trimethoprim or gentamicin, or
non-steroidal anti-inflammatory drugs, which are even
contraindicated in HFrEF) [1]. Worsening renal function
is common during initiation and up-titration of RAAS in-
hibitors [1]. Usually, the reduction in renal function is mi-
nor and should not lead to treatment discontinuation [1].
However, patients showing a substantial increase in serum
creatinine levels (50% above baseline, 266 μmol/l / 3 mg/
dl or estimated glomerular filtration rate <25 ml/min/1.73
m2) should be evaluated thoroughly and assessed for possi-
ble renal artery stenosis, excessive hyper- or hypovolaemia
and concomitant medication [1].
Limitations
Many recommendations provided in this review are sup-
ported by the latest European Society of Cardiology and
American Heart Association / American College of Cardi-
ology guidelines for the management of patients with HF
(see also fig. 1). However, as we tried to provide as con-
crete and specific suggestions as possible to facilitate im-
Table 2: Target doses and contraindications of common therapies for HFrEF patients, according to the Swiss Summary of Product Characteristics.
Class Class contraindications Drug Target Dose Up-titration in-
terval [30]
Specific contraindications
ACEI Hypersensitivity (hereditary angio-oede-
ma, or angio-oedema in the past during
therapy with ACEI/ARB), combination with
aliskirene in DM II/renal insufficiency,
pregnancy/breastfeeding
Enalapril [31] 10–20 mg
b.i.d.
2–4 weeks –
Lisinopril [32] 5–20 mg o.d.
Perindopril[29] 2.5–5.0 mg
o.d.
Dialysis and haemofiltration
Ramipril [33] 10 mg o.d. Dialysis and hemofiltration, uni- or bilateral
renal stenosis, creatinine clearance <20 ml/
min
ARB Candesartan [34] 32 mg o.d. Severe hepatic impairment and/or cholesta-
sisLosartan [35] 150 mg o.d.
Valsartan [36] 160 mg b.i.d. Creatinine clearance <10 ml/min
ARNI Sacubitril/Valsartan [37] 200 mg b.i.d. eGFR <10ml/min
BB Hypersensitivity, AV-block 2nd/3rd degree;
sick sinus syndrome, sinoatrial block,
symptomatic bradycardia (<60 beats/min)
before initiation; symptomatic hypotension
(<100 mm Hg) before initiation, severe
pAVK / Raynaud’s syndrome, severe
bronchial asthma, untreated phaeochro-
mocytoma, metabolic acidosis
Bisoprolol† [38] 10 mg o.d. Hepatic insufficiency/impairment, acute de-
compensated heart failure, cardiogenic
shock, pregnancy/breastfeeding, bradycar-
dia (<50 beats/minutes)
Stable dose of diuretics, digoxin, ACEi, ARB
for at least 2 weeks before initiating of
nebivolol
Carvedilol† [39] 25–100 mg‡
b.i.d.
Metoprolol succinate† [40] 200 mg o.d.
Nebivolol† [41] 10 mg o.d.
MRA* Hypersensitivity, hyperkalaemia Spironolactone [42] 25–50 mg o.d. 4 weeks Acute renal failure (creatinine clearance
<30ml/ml), anuria, Addison’s disease, hy-
ponatraemia, combination with eplerenone
Eplerenone [43] 50 mg o.d. Potassium >5.0 mmol/l before initiation,
eGFR <30 ml/min/1.73m2), hepatic insuffi-
ciency (Child-Pugh C), combination with
potassium-sparing diuretics, Cyp3A4-in-
hibitors, potassium supplements, dual RAAS
blockade
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; Av = atrioventricular; BB = beta blocker;
DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; pAVK =
peripheral arterial occlusive diseases *MRA in combination with ARB/ACEI usual daily dose: 50 mg; MRA without combination of ACEi/ARB: 100–200 mg. † Common contraindi-
cations cited, individual contraindications should be checked with the Swiss Prescribing Information. ‡ Target dose 2 × 50mg, if >85kg
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Table 3: Adjustment of HF medication in the case of adverse events. Adapted from Ponikowski et al. 2016 [1, 44].
Adverse event ACEI/ARB/ARNI BB MRA Diuretic
Worsening signs or symptoms (increas-
ing dyspnoea, fatigue, oedema, weight
gain)
In patients with signs of in-
creasing congestion, the di-
uretic dose should be in-
creased.
In the event of severe dete-
rioration, the BB dose
should be reduced to 50%.
In the case of marked fa-
tigue, the BB dose should
be reduced to 50% and it
should be taken in the
night. The patient should
be reassessed within 1–2
weeks.
Asymptomatic hypotension No change in therapy required. Dose may be reduced if the
patient shows no signs or
symptoms of congestion.
Symptomatic hypotension Dizziness and light-headedness are common adverse events and improve over time.
Reduce the dose if the patient experiences dizziness or light-headedness without showing signs or symptoms of congestion.
Dose adaption of diuretics, antihypertensive medication [44]; treatment with nitrates, calcium-channel blockers and other vasodilators
should be stopped or the dose reduced.
If the patient shows no signs or symptoms of congestion, a reduction of the diuretic dose can be considered.
Alternative causes for hypotension, e.g. hypovolaemia, should be treated [44].
Cough ACEI-induced cough does not usually
require a change in therapy. However,
substitution of an ARB is recommend-
ed in case of troublesome, ACEI-in-
duced cough
Worsening renal function Concomitant nephrotoxic drugs, includ-
ing NSAIDs should be stopped if urea
or creatinine levels rise excessively.
ACEI (or ARB) dose should be reduced
to half and blood chemistry re-checked
within 1–2 weeks if the rise in creati-
nine levels persists at 50% above
baseline, 266 μmol/l (3 mg/dl) or eGFR
<25 ml/min/1.73 m2.
ACEI (or ARB) therapy should be
stopped if creatinine levels increase by
>100%, to >310 μmol/l (3.5 mg/d-) or
eGFR <20 ml/min/1.73 m2.
ARNI therapy (Swiss Summary of
Product Characteristics):
In the case of renal dysfunction, con-
comitant medication should be evaluat-
ed and a temporary dose reduction or
withdrawal of ARNI is recommended
[44].
ARNI therapy is contra-indicated in pa-
tients with eGFR <10ml/min/1.73m [1,
44].
No change in therapy re-
quired.
Due to an increased risk of re-
nal dysfunction, the triple com-
bination of an ACEi, ARB and
MRA is not recommended.
Nephrotoxic drugs such as
NSAIDs should be avoided.
Male HF patients treated with
spironolactone should be
switched to eplerenone if they
develop breast discomfort or
gynaecomastia.
Thiazide diuretic therapy
should be stopped if used with
concomitant loop diuretics.
A reduction of the diuretic
dose should be considered if
urea or creatinine creatinine
levels rise excessively.
Thiazide diuretic therapy
should be stopped if used with
concomitant loop diuretics.
Hyperkalaemia Potassium supplements or retaining
agents should be stopped. A reduction
of the diuretic dose should be consid-
ered if potassium levels rise excessive-
ly, if there are no signs of congestion.
Close monitoring of potassium levels is
recommended especially for patients
with risk factors: severe renal insuffi-
ciency, diabetes mellitus, hyperaldos-
teronism [44].
If the increase in potassium levels per-
sists above ≥5.5 mmol/l, the ACEI (or
ARB) dose should be reduced to half
and blood chemistry re-checked within
1–2 weeks.
ACEI (or ARB) therapy should be
stopped temporarily if potassium levels
rise to >6.0 mmol/l.
In the event of hyperkalaemia, con-
comitant medication should be evaluat-
ed and a temporary dose reduction or
withdrawal of ARNI is recommended
[44]
No change in therapy re-
quired.
The triple combination of an
ACEI, ARB and MRA is not
recommended.
Other potassium-sparing or -re-
taining agents should be avoid-
ed.
Some low-salt supplements
can lead to increased serum
potassium levels.
Normal-to-high potassium lev-
els are described in HF pa-
tients if they are receiving
digoxin.
Hypokalaemia or hypomagnaesaemia The ACEI or ARB dose should be increased.
MRA should be added.
Potassium/magnesium supplements
Hyponatraemia If the patient is volume deplet-
ed, either:
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Adverse event ACEI/ARB/ARNI BB MRA Diuretic
‒ stop treatment with thiazide
‒ switch to a loop diuretic
‒ reduce the dose of loop di-
uretics
‒ stop treatment with loop di-
uretics
If the patient is volume over-
loaded:
‒ increase the loop diuretic
dose
‒ consider ultrafiltration
‒ consider i.v. inotropic sup-
port
‒ consider treatment with an
AVP antagonist
Advise the patient to restrict
fluids.
Hypovolaemia or dehydration The diuretic dose may be re-
duced depending on the vol-
ume status.
Insufficient diuretic response or diuretic
resistance
Consider adding an MRA or increasing the MRA dose.
The diuretic (loop, thiazides, non-thiazide-sulphonamide) dose
should be increased.
The loop diuretic should be administered more frequently or on
empty stomach
Loop diuretics may be combined with thiazide or metolazone.
Patients on furosemide may be switched to bumetanide or
torasemide.
Ultrafiltration or short term i.v. infusion of loop diuretic can be
considered.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; AVP = arginine vasopressin; BB = beta-blocker; eGFR = estimated glomerular filtration
rate; HF = heart failure; i.v. = intravenous; MRA = mineralocorticoid receptor antagonist; NSAID = nonsteroidal anti-inflammatory drug
plementation into routine clinical care, we also wish to
highlight that some recommendations provided by this ex-
pert group are expert opinion only and not yet supported
by data from prospective outcome studies.
Conclusions
Managing HF successfully after hospital discharge re-
quires a seamless interaction between the patient, the GP
and the cardiologist [15]. In particular, the transition phase
after hospital discharge is a critical and vulnerable phase
in the management of HF [45]. Here, both GPs and car-
diologists have an important role in monitoring and treat-
ing HF patients. In this article, we provide a summary
of recommendations on how to up-titrate HF medication,
which clinical and biomedical parameters to assess during
the follow-up visits and how the patients can contribute
to optimising their treatment outcomes. A well-structured
transition phase is critical in HF management and the man-
agement of chronic diseases in general, especially consid-
ering that the proportion of patients with chronic diseases
is continuously increasing [46].
Clinical relevance
Heart failure is a serious chronic disease associated with
frequent hospitalisation [1–4]. The transition from hospital
to primary care is a critical and vulnerable phase requiring
close collaboration between patient, GP and cardiologist
[1]. A cornerstone of follow-up care is the up-titration of
HF medication. However, only a minority of HF patients
achieve the target dose for ACEi and beta-blockers [28].
This article provides both GPs and cardiologists with sug-
gested up-titration strategies and the optimal management
of adverse events in an attempt to further improve HF man-
agement in Switzerland.
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